This journal has adopted the following models:
- Creative Commons Attribution License (CC-BY 2.0 UK)
- Publication Integrity and Ethics (P.I.E.) Guidelines
- Ethical Rules of Disclosure of the Association for Medical Ethics (AME)
- ICMJE Recommendations of the International Committee of Medical Journal Editors (ICMJE)
- Editorial Policy Statements of the Council of Science Editors (CSE)
Tracked/indexed by:
Google Scholar, EZB Nutzeranfragen, RoMEO, CrossRef, CNKI, J-Gate
OAPL (UK) archiving provider: British Library
Our publisher has negotiated a discount for its editors, reviewers and authors to undertake (distant learning- fully online) short courses related to research integrity and publication ethics, law and medical ethics, research governance, good ethical practice, leadership and management. These courses are approved by the Publication Integrity & Ethics.
A UK-based not-for-profit organization promoting integrity and ethics in the publishing sector through its guidelines and code of conduct.
P.I.E.'s main aim is to pave the way for a better publishing ethical environment that sets out the standards of a good and ethical editorial behaviour.
Whilst P.I.E. (π) promotes editorial freedom, at the same time, it also ensures that this freedom is not violated by editorial misconduct and plagiarism.
OAPL authors may choose to include the
OAPL standard ethics statements
in their submitted articles. It is assumed that all submitted original research studies, research studies, hypothesis, methodologies, short communications, case studies, case reports & case series have been conducted to the highest ethical standards.
Sakurai K, Hoang M, Kim Y, Mathiyakom N, Kim Y. DNA methylation and chromatin dynamics in embryonic stem cell regulation. OA Stem Cells 2014 May 18;2(1):8.
High Impact
Oikari LE, Griffiths LR, Haupt LM. The current state of play in human neural stem cell models: what we have learnt from the rodent. OA Stem Cells 2014 Apr 08;2(1):7.
High Impact
Ruiz JLM, Levy D, Bydlowski SP. Controversies regarding cancer stem cells. OA Stem Cells 2014 Mar 22;2(1):6.
High Impact
Wu XX, Shao JZ, Xiang C. Generation of pancreatic β cells from mesenchymal stem cells to treat type 1 diabetes. OA Stem Cells 2014 Mar 22;2(1):5.
High Impact
Dan S, Haibo L, Hong L. Pathogenesis and stem cell therapy for premature ovarian failure. OA Stem Cells 2014 Feb 10;2(1):4.
High Impact
Kyurkchiev DS. Cancer stem cells from glioblastoma multiforme: culturing and phenotype. OA Stem Cells 2014 Feb 10;2(1):3.
High Impact
Li Q, Fu X. Immunogenicity and tumorigenicity of human pluripotent stem cells. OA Stem Cells 2014 Jan 18;2(1):2.
High Impact
Montgomery A, Agbay A, Edgar JM, Gabers N, Gomez J, Mohtaram NK, King C, Mitchell A, Rajwani A, Rattray D, Robinson M, Shapka A, Sun L, Wong A, Willerth SM. Combining protein-based biomaterials with stem cells for spinal cord injury repair. OA Stem Cells 2014 Jan 18;2(1):1.
High Impact
Tura-Ceide O. Endothelial progenitor cells in chronic obstructive pulmonary disease. OA Stem Cells 2013 Nov 01;1(1):5.
High Impact
Akhtar S. c-kit-positive cardiac stem cells as a potential candidate for heart repair, developments, challenges and future implications. OA Stem Cells 2013 Oct 01;1(1):4.
High Impact
Byrne JA. Overcoming clinical hurdles for autologous pluripotent stem cell-based therapies. OA Stem Cells 2013 Sep 01;1(1):3.
High Impact
Shi G. Differentiation of human pluripotent stem cells into functional cells. OA Stem Cells 2013 Aug 01;1(1):2.
High Impact
Almelkar SI, Divate S, Chaudhari S. Peripheral venous blood mononucleated cells have potential to commit to progenitor endothelial cells when exposed to vascular endothelial growth factor. OA Stem Cells 2013 Aug 01;1(1):1.
High Impact
Dan S, Haibo L, Hong L. Pathogenesis and stem cell therapy for premature ovarian failure. OA Stem Cells 2014 Feb 10;2(1):4.
High Impact
Kyurkchiev DS. Cancer stem cells from glioblastoma multiforme: culturing and phenotype. OA Stem Cells 2014 Feb 10;2(1):3.
High Impact
Wu XX, Shao JZ, Xiang C. Generation of pancreatic β cells from mesenchymal stem cells to treat type 1 diabetes. OA Stem Cells 2014 Mar 22;2(1):5.
High Impact
Byrne JA. Overcoming clinical hurdles for autologous pluripotent stem cell-based therapies. OA Stem Cells 2013 Sep 01;1(1):3.
High Impact
Tura-Ceide O. Endothelial progenitor cells in chronic obstructive pulmonary disease. OA Stem Cells 2013 Nov 01;1(1):5.
High Impact
Akhtar S. c-kit-positive cardiac stem cells as a potential candidate for heart repair, developments, challenges and future implications. OA Stem Cells 2013 Oct 01;1(1):4.
High Impact
Li Q, Fu X. Immunogenicity and tumorigenicity of human pluripotent stem cells. OA Stem Cells 2014 Jan 18;2(1):2.
High Impact
Sakurai K, Hoang M, Kim Y, Mathiyakom N, Kim Y. DNA methylation and chromatin dynamics in embryonic stem cell regulation. OA Stem Cells 2014 May 18;2(1):8.
High Impact
Ruiz JLM, Levy D, Bydlowski SP. Controversies regarding cancer stem cells. OA Stem Cells 2014 Mar 22;2(1):6.
High Impact
Oikari LE, Griffiths LR, Haupt LM. The current state of play in human neural stem cell models: what we have learnt from the rodent. OA Stem Cells 2014 Apr 08;2(1):7.
High Impact
Almelkar SI, Divate S, Chaudhari S. Peripheral venous blood mononucleated cells have potential to commit to progenitor endothelial cells when exposed to vascular endothelial growth factor. OA Stem Cells 2013 Aug 01;1(1):1.
High Impact
Montgomery A, Agbay A, Edgar JM, Gabers N, Gomez J, Mohtaram NK, King C, Mitchell A, Rajwani A, Rattray D, Robinson M, Shapka A, Sun L, Wong A, Willerth SM. Combining protein-based biomaterials with stem cells for spinal cord injury repair. OA Stem Cells 2014 Jan 18;2(1):1.
High Impact
Shi G. Differentiation of human pluripotent stem cells into functional cells. OA Stem Cells 2013 Aug 01;1(1):2.
High Impact
Sakurai K, Hoang M, Kim Y, Mathiyakom N, Kim Y. DNA methylation and chromatin dynamics in embryonic stem cell regulation. OA Stem Cells 2014 May 18;2(1):8.
High Impact
Oikari LE, Griffiths LR, Haupt LM. The current state of play in human neural stem cell models: what we have learnt from the rodent. OA Stem Cells 2014 Apr 08;2(1):7.
High Impact
Ruiz JLM, Levy D, Bydlowski SP. Controversies regarding cancer stem cells. OA Stem Cells 2014 Mar 22;2(1):6.
High Impact
Wu XX, Shao JZ, Xiang C. Generation of pancreatic β cells from mesenchymal stem cells to treat type 1 diabetes. OA Stem Cells 2014 Mar 22;2(1):5.
High Impact
Dan S, Haibo L, Hong L. Pathogenesis and stem cell therapy for premature ovarian failure. OA Stem Cells 2014 Feb 10;2(1):4.
High Impact
Kyurkchiev DS. Cancer stem cells from glioblastoma multiforme: culturing and phenotype. OA Stem Cells 2014 Feb 10;2(1):3.
High Impact
Li Q, Fu X. Immunogenicity and tumorigenicity of human pluripotent stem cells. OA Stem Cells 2014 Jan 18;2(1):2.
High Impact
Montgomery A, Agbay A, Edgar JM, Gabers N, Gomez J, Mohtaram NK, King C, Mitchell A, Rajwani A, Rattray D, Robinson M, Shapka A, Sun L, Wong A, Willerth SM. Combining protein-based biomaterials with stem cells for spinal cord injury repair. OA Stem Cells 2014 Jan 18;2(1):1.
High Impact
Tura-Ceide O. Endothelial progenitor cells in chronic obstructive pulmonary disease. OA Stem Cells 2013 Nov 01;1(1):5.
High Impact
Akhtar S. c-kit-positive cardiac stem cells as a potential candidate for heart repair, developments, challenges and future implications. OA Stem Cells 2013 Oct 01;1(1):4.
High Impact
Byrne JA. Overcoming clinical hurdles for autologous pluripotent stem cell-based therapies. OA Stem Cells 2013 Sep 01;1(1):3.
High Impact
Shi G. Differentiation of human pluripotent stem cells into functional cells. OA Stem Cells 2013 Aug 01;1(1):2.
High Impact
Almelkar SI, Divate S, Chaudhari S. Peripheral venous blood mononucleated cells have potential to commit to progenitor endothelial cells when exposed to vascular endothelial growth factor. OA Stem Cells 2013 Aug 01;1(1):1.
High Impact
